Skip to main content
FDA OKs Illumina's Vectibix companion Dx on MiSeqDx system

The FDA has given Illumina approval for its Extended RAS Panel for use on its MiSeqDx system. The test, which is expected to start shipping in the third quarter, helps determine whether patients with metastatic colorectal cancer will respond to Amgen's Vectibix by evaluating 56 variants in the NRAS and KRAS genes.

Full Story: